Contact Us
Drug Search Results
More Filters [+]

Dinaciclib

Alternative Names: dinaciclib, sch 727965
Latest Update: 2024-08-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dinaciclib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

Phase 2: Non-Small-Cell Lung Cancer|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Prolymphocytic B-Cell Leukemia|Breast Cancer|Melanoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia|Lymphoma, B-Cell|Multiple Myeloma|Mantle-Cell Lymphoma|Lentigo|Hutchinson's Melanotic Freckle

Phase 1: Pancreatic Cancer|Multiple Myeloma|Acute Myeloid Leukemia|Adenocarcinoma|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Triple Negative Breast Cancer|Diffuse Large B-Cell Lymphoma|Male Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
M16-183

P1

Terminated

Acute Myeloid Leukemia

2022-12-01

28%
NCI-2018-01053

P1

Completed

Triple Negative Breast Cancer

2020-06-30

KEYNOTE-155

P1

Terminated

Chronic Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma

2020-04-06

NCI-2012-01737

P1

Completed

Multiple Myeloma

2016-11-22

Recent News Events

Date

Type

Title

05/08/2024

PubMed

 Selective but not pan-CDK inhibition abrogates 5-FU-driven tissue factor upregulation in colon cancer.

05/01/2024

PubMed

 Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.

05/01/2024

PubMed

 CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.

12/11/2021

News Article

 Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

06/28/2020

News Article

 Cell Publication Elucidates How SARS-CoV-2 Dramatically Rewires Important Cell Programming; Identifies Existing Therapeutics That May Fight COVID-19

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions